JP7551500B2 - ヘテロタンデム二環式ペプチド複合体 - Google Patents

ヘテロタンデム二環式ペプチド複合体 Download PDF

Info

Publication number
JP7551500B2
JP7551500B2 JP2020554265A JP2020554265A JP7551500B2 JP 7551500 B2 JP7551500 B2 JP 7551500B2 JP 2020554265 A JP2020554265 A JP 2020554265A JP 2020554265 A JP2020554265 A JP 2020554265A JP 7551500 B2 JP7551500 B2 JP 7551500B2
Authority
JP
Japan
Prior art keywords
μmol
equiv
seq
compound
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520378A (ja
Inventor
キーン，ニコラス
マクドネル，ケヴィン
パーク，ピーター
ウパディヤヤ，プニット
マッド，ジェンマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1805492.4A external-priority patent/GB201805492D0/en
Priority claimed from GBGB1820981.7A external-priority patent/GB201820981D0/en
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2021520378A publication Critical patent/JP2021520378A/ja
Priority to JP2024015762A priority Critical patent/JP2024062998A/ja
Application granted granted Critical
Publication of JP7551500B2 publication Critical patent/JP7551500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020554265A 2018-04-04 2019-04-02 ヘテロタンデム二環式ペプチド複合体 Active JP7551500B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015762A JP2024062998A (ja) 2018-04-04 2024-02-05 ヘテロタンデム二環式ペプチド複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1805492.4A GB201805492D0 (en) 2018-04-04 2018-04-04 Heterotandem Bicyclic peptide complexes
GB1805492.4 2018-04-04
GBGB1820981.7A GB201820981D0 (en) 2018-12-21 2018-12-21 Heterotandem bicyclic peptide complexes
GB1820981.7 2018-12-21
PCT/GB2019/050951 WO2019193328A1 (en) 2018-04-04 2019-04-02 Heterotandem bicyclic peptide complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015762A Division JP2024062998A (ja) 2018-04-04 2024-02-05 ヘテロタンデム二環式ペプチド複合体

Publications (2)

Publication Number Publication Date
JP2021520378A JP2021520378A (ja) 2021-08-19
JP7551500B2 true JP7551500B2 (ja) 2024-09-17

Family

ID=66175434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554265A Active JP7551500B2 (ja) 2018-04-04 2019-04-02 ヘテロタンデム二環式ペプチド複合体
JP2024015762A Pending JP2024062998A (ja) 2018-04-04 2024-02-05 ヘテロタンデム二環式ペプチド複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015762A Pending JP2024062998A (ja) 2018-04-04 2024-02-05 ヘテロタンデム二環式ペプチド複合体

Country Status (12)

Country Link
US (2) US11453703B2 (enExample)
EP (1) EP3774851A1 (enExample)
JP (2) JP7551500B2 (enExample)
KR (1) KR20200139236A (enExample)
CN (1) CN112236442A (enExample)
AU (2) AU2019247795B2 (enExample)
BR (1) BR112020020349A2 (enExample)
CA (1) CA3095582A1 (enExample)
IL (1) IL277717A (enExample)
MX (1) MX2020010444A (enExample)
SG (1) SG11202009773VA (enExample)
WO (1) WO2019193328A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024062998A (ja) * 2018-04-04 2024-05-10 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
WO2020128526A1 (en) * 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (en) * 2019-08-13 2022-06-22 BicycleTX Limited Modified multimeric bicyclic peptide ligands
CN119192401A (zh) * 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
GB201914872D0 (en) * 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
AU2022206577A1 (en) * 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
MX2024002098A (es) * 2021-08-17 2024-03-05 Medshine Discovery Inc Conjugado farmaco-polipeptido con estructura innovadora y su aplicacion.
TWI803993B (zh) * 2021-09-28 2023-06-01 廖嘉鴻 環胜肽自組裝3d微粒裝置及其製造方法
JP7774349B2 (ja) * 2021-09-29 2025-11-21 星聯▲タイ▼（珠海）生物科技有限公司 三環式ポリペプチド複合体薬物及びその使用
CN115819618B (zh) * 2022-09-16 2023-10-27 哈尔滨工业大学 一种光激活的纳抗偶联物二聚化诱导剂pancid及其应用
WO2025248261A1 (en) 2024-05-31 2025-12-04 Bicycletx Limited Method for identifying patients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518807A (ja) 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2016527180A (ja) 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
JP2018502825A (ja) 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
AU2010306774A1 (en) * 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
CN103906865B (zh) * 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
KR20200139236A (ko) * 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN119192401A (zh) 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518807A (ja) 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2016527180A (ja) 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
JP2018502825A (ja) 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bicycle Therapeutics to Present New BT1718 Data in the "New Drugs on the Horizon" Session at the 2018 American Association for Cancer Research Meeting，Businesswire，2018年04月03日，インターネット：＜URL :https://www.businesswire.com/news/home/201804 03005152/en/Bicycle-Therapeutics-to-Present-New-BT1718-Data-in-the-New-Drugs-onthe- Horizon-Session-at-the-2018-American-Association-for-Cancer-Research-Meeting ＞

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024062998A (ja) * 2018-04-04 2024-05-10 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体

Also Published As

Publication number Publication date
US20190307836A1 (en) 2019-10-10
SG11202009773VA (en) 2020-10-29
BR112020020349A2 (pt) 2021-01-05
US11453703B2 (en) 2022-09-27
WO2019193328A1 (en) 2019-10-10
CA3095582A1 (en) 2019-10-10
JP2021520378A (ja) 2021-08-19
US20230008076A1 (en) 2023-01-12
AU2019247795B2 (en) 2024-08-15
AU2024205105A1 (en) 2024-10-10
AU2019247795A1 (en) 2020-11-12
CN112236442A (zh) 2021-01-15
JP2024062998A (ja) 2024-05-10
US20210299210A2 (en) 2021-09-30
EP3774851A1 (en) 2021-02-17
IL277717A (en) 2020-11-30
MX2020010444A (es) 2021-01-08
KR20200139236A (ko) 2020-12-11

Similar Documents

Publication Publication Date Title
JP7551500B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7704732B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7770607B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7404241B2 (ja) ＥｐｈＡ２に特異的な二環ペプチドリガンド
JP2024023291A (ja) 多量体二環式ペプチドリガンド
CN113474046A (zh) Il-17特异性的双环肽配体
WO2024261490A1 (en) Bicyclic peptide ligands specific for nk cells
EA045834B1 (ru) Гетеротандемные бициклические пептидные комплексы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240904

R150 Certificate of patent or registration of utility model

Ref document number: 7551500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150